RecruitingPhase 1NCT04337177
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Studying Embryonal rhabdomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Valent Technologies, LLC
- Principal Investigator
- Lars Wagner, M.D., MDDuke University Children's Hospital & Health Center
- Intervention
- VAL-413(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 1-30 years · All sexes
- Timeline
- 2021 – 2026
Study locations (8)
- UCSF, Mission Bay - Benioff Children's Hospital, San Francisco, California, United States
- Children's National Research Institute - Children's National Hospital, Washington D.C., District of Columbia, United States
- Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, Indiana, United States
- University of North Carolina at Chapel Hill - North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
- Atrium Health Levine Children's Hospital - Carolinas Medical Center, Charlotte, North Carolina, United States
- Duke University Children's Hospital and Health Center, Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Sarah Cannon Research Institute, Pediatric Hematology & Oncology, Nashville, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04337177 on ClinicalTrials.govOther trials for Embryonal rhabdomyosarcoma
Additional recruiting or active studies for the same condition.